AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Application of FIT-DNA Detection in Following Colorectal Cancer Resection-Implications for Surveillance

Recruitingn/aAges 18 Years - 80 YearsAllSun Yat-sen University
💬

In plain words

What the trial is, and whether it could suit you

Colorectal cancer (CRC) is a common cancer that threatens human health, with the incidence ranking the third in the world. 70% of patients are in the middle and late stages whendiagnosed, and even after radical surgery, 30% - 50% of patients with CRC have recurrence or metastasis after radical surgery. Therefore, after radical surgery and adjuvant chemotherapy, regular monitoring of CRC patients should be paid attention to in order to detect the recurrence and metastasis lesions that can be resected and the early non-invasive metachronous multiple primary tumors. The sensitivity of FIT-DNA to CRC was 95.5%, the sensitivity to advanced adenoma (AA) was 63.5%, and the specificity was 87.5%, showing a good ability to screen colorectal cancer and precancerous lesions. At present, there is no report on the application of FIT-DNA combined detection technology in the high-risk recurrence peri

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * 1). The pathological diagnosis was colorectal adenocarcinoma; 2). Age: 18 to 80 years old,allgenders; 3). Radical surgery for CRC is required; 4). No preoperative antitumor therapy (including chemotherapy, radiation therapy, targeted therapy, and immunotherapy); 5). Preoperative examination revealed no distant metastasis; 6). There were no severe hemorrhoids or other known conditions that can cause gastrointestinal bleeding before surgery; 7). The clinical treatment data were complete; Exclusion Criteria: * 1). With a history of digestive tract tumors other than CRC; 2). Previous colorectal surgery; 3). Patients requiring a fistula; 4). With complete intestinal obstruction or perforation; 5). Women who are pregnant or breastfeeding; 6). Patients with metastases found in other sites during surgery that cannot be removed radically; 7). Patients unwilling or unable to sign an informed consent form; 8). A strict vegetarian; 9). Patients who are unwilling to follow up according to the protocol or have poor follow-up compliance; 10). Any conditions that the study physician deemed inappropriate for inclusion。 Exit or terminate criteria: 1. . Follow-up information for the patients was not available 2. . Distant metastasis was diagnosed after surgery 3. . Subjects died before the end of follow-up.
💊

What it tests

  • Not listed
📍

Where

1 site
Colorectal Department,SunYat-sen University Cancer Center
Guangzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy